Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-263 (nivolumab biosimilar) vs Opdivo in advanced melanoma
NCT06112808Phase 1Active, not recruiting
- Sponsor
- BIOCAD
- Start
- May 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BCD-263 in melanoma (2 arms), sponsored by BIOCAD. Primary endpoint: Area Under the Curve (0-672h). Started May 2023; status: active, not recruiting.
02
Drugs
BCD-263
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06112808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112808.